3-v Biosciences, Inc.

Myokardia, Inc.

Sunesis Pharmaceuticals, Inc.

Saginiet Biosciences Inc.

Sagimet Biosciences Inc.

Marc Evanchik

Robert S McDowell

Johan D Oslob

Haiying Cai

Hanbiao Yang

Cristiana A Zaharia

Lily W Hu

Russell J Johnson

Yonghong Song

Allan S Wagman

Brian Kane

Danielle Aubele

Jonathan Charles Fox

Robert G Anderson

Arvinder Sran

Hector Rodriguez

Gregory Duke

Anantha R Sudhakar

Jeffrey William Jacobs

Jeffrey A Silverman

Daniel C Adelman

Puping Lu

Timothy Sean Heuer

Yamini Ohol-Gupta

Marie O'Farrell

Douglas I Buckley

Min Zhong

Mark Grillo

Pu-Ping Lu

Robert Mcdowell

Marie O'FARRELL

Yamini Ohol

Eric Green

Johan Oslob

Robert Anderson

Marie O'farrell

David Zhang

Timothy Carlson

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Pyrimidinedione compounds

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

Heterocyclic modulators of lipid synthesis

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

Heterocyclic modulators of lipid synthesis and combinations thereof

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.

Compounds and compositions for treatment of cancer

The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

Bicyclic-pyrimidinedione compounds

The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

Cycloalkyl-substituted pyrimidinedione compounds

Growing community of inventors

San Jose, CA, United States of America

Marc Evanchik